Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 23.6% in November

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 78,900 shares, a decline of 23.6% from the November 15th total of 103,300 shares. Based on an average trading volume of 2,830,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.9% of the shares of the stock are sold short.

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP purchased a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.17% of the company’s stock.

Analyst Ratings Changes

Separately, Maxim Group decreased their price objective on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Theriva Biologics Stock Down 0.8 %

Shares of NYSEAMERICAN TOVX opened at $1.18 on Monday. The stock has a market cap of $3.28 million, a PE ratio of -0.04 and a beta of 1.33. Theriva Biologics has a 12 month low of $1.14 and a 12 month high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($6.81) earnings per share for the quarter, missing the consensus estimate of ($6.25) by ($0.56).

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.